AtlasInfectionsOther infectious diseases

Pertussis

4Curable or preventable in mostAI-generated
Burden-over-time charts — how many people this disease affects and whether that number is rising or falling — are coming to this page. The treatability read, milestones, and live trial pipeline below are current.

Milestones

dot size = significance
199020002010202020251996 — Hepatitis b virus hbsag surface protein antigen approved (FDA)1997 — Bordetella pertussis filamentous hemagglutinin approved (FDA)1997 — Bordetella pertussis pertactin autotransporter approved (FDA)1999 — Bordetella pertussis toxin approved (FDA)
1996: Drug approval — Hepatitis b virus hbsag surface protein antigen approved (FDA). 1997: Drug approval — Bordetella pertussis filamentous hemagglutinin approved (FDA). 1997: Drug approval — Bordetella pertussis pertactin autotransporter approved (FDA). 1999: Drug approval — Bordetella pertussis toxin approved (FDA)

What's being tested now

2001: 1 trials started2018: 1 trials started2021: 1 trials started2022: 1 trials started2023: 4 trials started2024: 3 trials started2025: 5 trials started2026: 5 trials started2010202020265

Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.

See all 17 active Pertussis trials on Clin2 →

Related

Burden estimates: IHME Global Burden of Disease Study. Drug indications: ChEMBL (CC BY-SA). Trial data: ClinicalTrials.gov via Clin2. Velocity, acceleration, and turning points are computed by Clin2 — how this page is made. Treatability describes what medicine can do, not what is available everywhere. This page describes populations, not people, and is not medical advice.